Rajendran Simon, McCluggage W Glenn
Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK (S.R., W.G.M.).
Int J Gynecol Pathol. 2022 Mar 1;41(2):191-202. doi: 10.1097/PGP.0000000000000788.
Ovarian endometrioid carcinoma, more than any other type of ovarian epithelial malignancy, demonstrates a varied morphology which can cause problems in diagnosis. In tubo-ovarian tumor pathology, WT1 is a commonly used marker as it is consistently expressed in low-grade and high-grade serous carcinomas and is often considered a specific marker of a serous phenotype. However, ovarian endometrioid neoplasms may also express WT1 which may contribute to misdiagnosis. We report our experience with 23 ovarian endometrioid neoplasms (4 borderline tumors, 19 carcinomas), mainly received in consultation, which were WT1 positive (diffuse in 11 cases) which often contributed to misdiagnosis. Endometriosis was identified in the same ovary in 6 cases and squamous elements in 7. We describe strategies for distinguishing such neoplasms, which may exhibit morphologic overlap with serous tumors, from low-grade and high-grade serous carcinomas and stress that a diagnosis of HGSC is unlikely with two grossly and histologically normal fallopian tubes. We also stress that a panel of markers should always be used rather than relying on a single marker and that when the morphology is classical of an endometrioid carcinoma, diagnostic immunohistochemistry is not needed given the potential for confusion in cases showing "aberrant" staining. We also discuss the phenomenon of "aberrant" immunohistochemical staining in endometrioid carcinomas which appears more common than in other ovarian carcinomas.
卵巢子宫内膜样癌与其他类型的卵巢上皮性恶性肿瘤相比,具有多样的形态,这可能会在诊断中造成问题。在输卵管卵巢肿瘤病理学中,WT1是一种常用标志物,因为它在低级别和高级别浆液性癌中持续表达,常被视为浆液性表型的特异性标志物。然而,卵巢子宫内膜样肿瘤也可能表达WT1,这可能导致误诊。我们报告了23例卵巢子宫内膜样肿瘤(4例交界性肿瘤,19例癌)的诊治经验,这些病例主要是会诊病例,均为WT1阳性(11例弥漫性阳性),这常常导致误诊。6例在同一卵巢中发现了子宫内膜异位症,7例发现了鳞状成分。我们描述了区分这类可能与浆液性肿瘤存在形态学重叠的肿瘤与低级别和高级别浆液性癌的策略,并强调如果双侧输卵管大体和组织学均正常,则不太可能诊断为高级别浆液性癌。我们还强调应始终使用一组标志物,而不是依赖单一标志物,并且当形态学表现为典型的子宫内膜样癌时,鉴于显示“异常”染色的病例可能存在混淆,不需要进行诊断性免疫组化。我们还讨论了子宫内膜样癌中“异常”免疫组化染色的现象,这种现象似乎比其他卵巢癌中更为常见。